SLC38A2 and breast carcinoma: Previous studies showed that the expression of SNAT2 was increased in ER+ breast cancer cell lines after 17β-estradiol (E2) stimulation, and an estrogen response element was described in the SNAT2 promoter in rat mammary glands during gestation (22, 23).